Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Exelixis and Ipsen will show up big in liver at ASCO GI
Company: Exelixis (EXEL) and Ipsen (IPSEY)
Therapy: Cabozantinib
Disease: Hepatocellular carcinoma (HCC, aka liver cancer)
News: EXEL announced that it will be presenting a late-breaking abstract detailing results from the phase 3